Quantcast

Latest glioblastoma multiforme Stories

2014-03-12 12:28:20

BETHESDA, Md., March 12, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO Feuerstein falsely accused NW Bio of manipulating its news by delaying announcement of the Hospital Exemption...

2014-03-11 08:29:44

Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/ -- Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most...

2014-03-10 08:30:14

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute ("PEI"- the FDA of Germany) of a "Hospital Exemption" early access program under Section 4b of the German Drug Law. Under this...

2014-03-07 23:00:56

iewei Ltd. solution starts at the base, raising awareness by making the invisible pollution visible — that is what iewei, the wellness wristband is all about. It is an “alert system” capable of measuring the wearer’s exposure to harmful radiation, in addition to monitoring heart rate and body temperature. (PRWEB) March 07, 2014 For the network operators 'Greed is good' was a phrase immortalized by Michael Douglas' in his Oscar-winning turn as the unscrupulous corporate...

2014-03-07 08:25:40

BETHESDA, Md., March 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned....

2014-03-06 08:29:14

NEW YORK, March 6, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals...

2014-03-05 23:03:44

Project Impact aims to fundamentally change the way new pediatric cancer therapies are developed and tested, through public policy and a funded research program. Boston, MA (PRWEB) March 05, 2014 National Brain Tumor Society, the largest nonprofit dedicated to the brain tumor community in the United States, today announced the launch of Project Impact: Driving Discovery to a Cure for Pediatric Brain Tumors, an integrated research and drug development program that seeks to confront the...

2014-03-04 08:31:55

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26(th) Annual ROTH Capital Conference. Mr. Bacha will make a corporate presentation to...

2014-02-26 23:02:51

Jumpstarting Brain Tumor Drug Development Coalition hosts seminal workshop with brain tumor patient advocates, leading neuro-oncologists, biopharmaceutical industry representatives, FDA, and NCI to advance strategies for establishing better pathways for therapy evaluation. Bethesda, MD (PRWEB) February 26, 2014 Leaders from key cross-sections of the neuro-oncology community came together at a recent Brain Tumor Clinical Trial Endpoints Workshop to confront a critical challenge in...

2014-02-26 08:28:38

Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 26, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 5 and advanced to Cohort 6. DelMar...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related